Ticker
ACOR

Price
0.62
Stock movement up
+0.01 (1.49%)
Company name
Acorda Therapeutics Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Drug Manufacturers-Specialty & Generic
Market cap
15.03M
Ent value
279.75M
Price/Sales
0.12
Price/Book
0.12
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-78.35%
3 year return
-61.08%
5 year return
-65.30%
10 year return
-42.27%
Last updated: 2022-11-29

DIVIDENDS

ACOR does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales0.12
Price to Book0.12
EV to Sales2.28

FINANCIALS

Per share

Loading...
Per share data
Current share count24.28M
EPS (TTM)-8.01
FCF per share (TTM)-2.38

Income statement

Loading...
Income statement data
Revenue (TTM)122.74M
Gross profit (TTM)87.95M
Operating income (TTM)-72.93M
Net income (TTM)-95.02M
EPS (TTM)-8.01
EPS (1y forward)-

Margins

Loading...
Margins data
Gross margin (TTM)71.65%
Operating margin (TTM)-59.41%
Profit margin (TTM)-77.42%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash31.87M
Net receivables11.99M
Total current assets80.45M
Goodwill0.00
Intangible assets328.23M
Property, plant and equipment0.00
Total assets424.14M
Accounts payable8.77M
Short/Current long term debt193.34M
Total current liabilities46.00M
Total liabilities296.59M
Shareholder's equity127.55M
Net tangible assets-200.68M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-28.10M
Capital expenditures (TTM)177.00K
Free cash flow (TTM)-28.27M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-74.50%
Return on Assets-22.40%
Return on Invested Capital-70.61%
Cash Return on Invested Capital-21.01%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open0.60
Daily high0.64
Daily low0.60
Daily Volume120K
All-time high267.00
1y analyst estimate10.00
Beta0.50
EPS (TTM)-8.01
Dividend per share-
Ex-div date-
Next earnings date7 Mar 2023

Downside potential

Loading...
Downside potential data
ACORS&P500
Current price drop from All-time high-99.77%-17.12%
Highest price drop-99.90%-56.47%
Date of highest drop29 Sep 20229 Mar 2009
Avg drop from high-45.05%-11.46%
Avg time to new high66 days13 days
Max time to new high1976 days1805 days
COMPANY DETAILS
ACOR (Acorda Therapeutics Inc) company logo
Marketcap
15.03M
Marketcap category
Small-cap
Description
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.
Employees
118
Investor relations
-
SEC filings
CEO
Ronald Cohen
Country
USA
City
Ardsley
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Acorda Therapeutics ( NASDAQ:ACOR ) Third Quarter 2022 Results Key Financial Results Revenue: US$33.5m (up 6.5% from 3Q...
November 19, 2022
PEARL RIVER, N.Y., November 11, 2022--Acorda Therapeutics Announces Passage of Reverse Stock Split Proposal at its Special Meeting of Stockholders
November 11, 2022
PEARL RIVER, N.Y., November 04, 2022--Acorda Therapeutics Announces Adjournment of Special Meeting of Stockholders
November 4, 2022
PEARL RIVER, N.Y., November 01, 2022--Acorda Therapeutics Reports Third Quarter 2022 Financial Results
November 1, 2022
PEARL RIVER, N.Y., October 27, 2022--Acorda Therapeutics Provides Long-Term Business Plan and Financial Guidance
October 27, 2022
PEARL RIVER, N.Y., October 25, 2022--Acorda Third Quarter 2022 Update: Webcast/Conference Call Scheduled for November 1, 2022
October 25, 2022
PEARL RIVER, N.Y., October 21, 2022--Acorda Shareholders Invited to Virtual Q&A with CEO Ron Cohen, M.D.
October 21, 2022
PEARL RIVER, N.Y., October 19, 2022--ISS, Glass Lewis, and Egan-Jones Recommend that Acorda Stockholders Vote FOR the Proposal to Implement a Reverse Stock Split
October 19, 2022
PEARL RIVER, N.Y., October 18, 2022--Acorda Therapeutics Will Not Use Shares for December 2022 $6.2 Million Interest Payment on Secured Debt
October 18, 2022
PEARL RIVER, N.Y., October 16, 2022--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that a three-judge arbitration panel has issued a final decision in a dispute with Alkermes PLC (Nasdaq: A...
October 16, 2022
Next page